|
|
Volumn 28, Issue 24, 2010, Pages
|
|
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BORTEZOMIB;
DOXORUBICIN;
MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;
RAPAMYCIN;
TEMSIROLIMUS;
TOPOTECAN;
ANTINEOPLASTIC AGENT;
BORONIC ACID DERIVATIVE;
DRUG DERIVATIVE;
MAMMALIAN TARGET OF RAPAMYCIN;
PROTEIN KINASE INHIBITOR;
PROTEIN SERINE THREONINE KINASE;
PYRAZINE DERIVATIVE;
SIGNAL PEPTIDE;
ADULT;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CANCER RESISTANCE;
CANCER SURGERY;
CASE REPORT;
FEMALE;
HUMAN;
LETTER;
LIVER RESECTION;
METASTASIS;
PERIVASCULAR EPITHELIOID CELL TUMOR;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
ADJUVANT CHEMOTHERAPY;
DISEASE COURSE;
DRUG EFFECT;
DRUG RESISTANCE;
METABOLISM;
MIDDLE AGED;
NOTE;
PHASE 1 CLINICAL TRIAL;
RETROPERITONEAL TUMOR;
TREATMENT FAILURE;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BORONIC ACIDS;
CHEMOTHERAPY, ADJUVANT;
CLINICAL TRIALS, PHASE I AS TOPIC;
DISEASE PROGRESSION;
DOXORUBICIN;
DRUG RESISTANCE, NEOPLASM;
FEMALE;
HUMANS;
INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS;
MIDDLE AGED;
PERIVASCULAR EPITHELIOID CELL NEOPLASMS;
PROTEIN KINASE INHIBITORS;
PROTEIN-SERINE-THREONINE KINASES;
PYRAZINES;
RETROPERITONEAL NEOPLASMS;
SIROLIMUS;
TOPOTECAN;
TREATMENT FAILURE;
|
|
EID: 77956240797
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2010.29.4678 Document Type: Letter |
|
Times cited : (49)
|
|
References (2)
|
